Biosimilars Need Better Reimbursement, Not 'Kabuki' Coverage, Gottlieb Tells Insurers
Executive Summary
Rebate arrangements that block biosimilar uptake under guise of lowering costs do patients no favors, US FDA Commissioner says at AHIP policy conference.
You may also be interested in...
FDA And FTC Offer Advice On Biosimilar Barriers
Speakers suggest ways to eliminate barriers to biosimilar uptake, but Janssen pushes back, saying there is need to inform physicians and patients of a biosimilar's interchangeability status. Biosimilar advocates want prescriber incentives, labeling changes, and FDA education on interchangeability.
FDA/FTC's Hot Ticket: Biosimilar Workshop On How To Boost Market, From Education To Lawsuits
Speakers suggest ways to eliminate barriers to biosimilar uptake, but Janssen pushes back, saying there is need to inform physicians and patients of a biosimilar's interchangeability status. Biosimilar advocates want prescriber incentives, labeling changes, and FDA education on interchangeability.
Lupin's Gupta On Getting Biosimilar Manufacturing Right, Albuterol Outlook
Lupin managing director Nilesh Gupta says manufacturing competence will be a “big advantage” in the biosimilars space, and also believes that the US albuterol market remains “very lucrative” despite the entry of authorized generics.